FerGene debuted less than a month ago, formed to support the launch of the bladder cancer gene therapy nadofaragene firadenovec, and on 5 December presented pivotal data showing an early and durable response in its Phase III trial.
The news gives Ferring Pharmaceuticals AS, FerGene’s parent company, a fast start for its first move into gene therapy. The privately held Swiss company Ferring and private equity firm Blackstone Medical Inc. launched FerGene with a $570m funding announced on 25 November. Ferring had licensed the gene therapy from Finland-based FKD Therapies OY, which had been developing the gene therapy, in May 2018, and the drug has already been submitted to the US Food and Drug Administration (FDA) and granted a priority review. (Also see "Ferring And Blackstone Launch Gene Therapy Company" - Scrip, 25 November, 2019
